Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi, Mengke Niu, Yuze Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 100

Showing 51-75 of 100 citing articles:

Nanoparticle targeting cGAS-STING signaling in disease therapy
Zhou Lan, Yu Huang, Yuzhang Wu, et al.
Nano Research (2024) Vol. 17, Iss. 8, pp. 7315-7336
Closed Access | Times Cited: 4
Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment
Susam Lee, Kyeong Hee Hong, Heewon Park, et al.
Journal of Controlled Release (2024) Vol. 373, pp. 55-69
Closed Access | Times Cited: 4
Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma
Zan Luo, Ying Li, Bin Xu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
In virto priming of the STING signaling pathway enhances the maturation and activation of dendritic cells induced by hepatitis B vaccine
Chaomin Ren, Xufeng Cui, Hui‐Xin Wang, et al.
Immunology Letters (2025) Vol. 272, pp. 106977-106977
Closed Access
Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets
Yutong Li, Mawieh Hamad, Eyad Elkord
Hepatology International (2025)
Closed Access
Increased expression of ECT2 predicts the poor prognosis of breast cancer patients
Ming Yi, Di Zhang, Bin Song, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 16
Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies
Tianye Li, Xinrun Wang, Shuang Qin, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114712-114712
Open Access | Times Cited: 10
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated
Zara Karami, Keywan Mortezaee, Jamal Majidpoor
International Immunopharmacology (2023) Vol. 122, pp. 110648-110648
Open Access | Times Cited: 10
From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer
Yibin Zhou, Fenglan Wang, Guangda Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response
Teenesha Chellen, Mathilde Bausart, Pierre Maus, et al.
Materials Today Bio (2024) Vol. 26, pp. 101057-101057
Open Access | Times Cited: 3
Effects of chronic stress on cancer development and the therapeutic prospects of adrenergic signaling regulation
Hao Zhang, Yuwei Yang, Yan Cao, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116609-116609
Open Access | Times Cited: 3
STING Agonist Delivered by Neutrophil Membrane-Coated Gold Nanoparticles Exerts Synergistic Tumor Inhibition with Radiotherapy
Dehua Lu, Wenhua Li, Jingyun Tan, et al.
ACS Applied Materials & Interfaces (2024)
Closed Access | Times Cited: 3
The cGAS-STING pathway drives neuroinflammation and neurodegeneration via cellular and molecular mechanisms in neurodegenerative diseases
Yuxin Zhang, Meijuan Zou, Hao Wu, et al.
Neurobiology of Disease (2024) Vol. 202, pp. 106710-106710
Open Access | Times Cited: 3
Activation of STING by SAMHD1 Deficiency Promotes PANoptosis and Enhances Efficacy of PD-L1 Blockade in Diffuse Large B-cell Lymphoma
Yiqing Cai, Xiaohong Chen, Tiange Lu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 14, pp. 4627-4643
Open Access | Times Cited: 8
GAS-STING: a classical DNA recognition pathways to tumor therapy
Xinrui Wang, Meijia Lin, Liping Zhu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
Shuping Yin, Han Cui, Shuang Qin, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115355-115355
Open Access | Times Cited: 7
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials
Dominik Kiem, Matthias Ocker, Richard Greil, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 3, pp. 229-242
Closed Access | Times Cited: 2
STING agonist, SMA-2, inhibits clear cell renal cell carcinoma through improving tumor microenvironment
Wei Wang, Fengqing Zhang, Yan Hu, et al.
Molecular and Cellular Biochemistry (2024) Vol. 479, Iss. 7, pp. 1697-1705
Open Access | Times Cited: 2
Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model
Lenore Monterroza, Maria M. Parrilla, Sarah G. Samaranayake, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5392-5392
Open Access | Times Cited: 2
Integrative analysis of pan-cancer single-cell data reveals a tumor ecosystem subtype predicting immunotherapy response
Shengjie Zeng, Liu-xun Chen, Jinyu Tian, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 2
Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody
Ming Yi, Tianye Li, Mengke Niu, et al.
Advanced Science (2024)
Open Access | Times Cited: 2
Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer
Yinghao Zhao, Shengnan Jia, Kun Zhang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer
Ali Sayadmanesh, Vahid Yekehfallah, Amir Valizadeh, et al.
International Immunopharmacology (2023) Vol. 125, pp. 111093-111093
Closed Access | Times Cited: 5
Polymeric STING Pro‐agonists for Tumor‐Specific Sonodynamic Immunotherapy
Jie Yu, Shasha He, Chi Zhang, et al.
Angewandte Chemie (2023) Vol. 135, Iss. 32
Closed Access | Times Cited: 4
Prognostic analysis of lung adenocarcinoma based on cancer-associated fibroblasts genes using scRNA-sequencing
Han Zhang, Yuhang Wang, Kai Wang, et al.
Aging (2023) Vol. 15, Iss. 14, pp. 6774-6797
Open Access | Times Cited: 4

Scroll to top